Canada Diabetes Care Drugs and Devices Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Drugs (by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by sub-segment (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors)) and Devices ( Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose (Hospital and Personal use) and Continuous Glucose Monitoring)).

Market Snapshot

Picture1
Study Period: 2018 - 2026
Base Year: 2020
CAGR: >5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Canada diabetes care Drugs and Devices market is expected to register a CAGR of above 5.3% during the forecast period (2019-2025).

  • Monitoring devices are anticipated to dominate the market during the forecast period, owing to the rising prevalence of diabetes and an increase in the number of device users in the country.
  • There has been a significant rise in insulin delivery systems technology, from insulin injections to insulin pumps.
  • Canada diabetes care devices market, the monitoring devices occupy the highest market share of 11.28% for the year 2019. The Self-monitoring blood glucose devices occupy the highest market share with test strips being highest in volume.

Scope of the Report

The market is segmented by Drugs (by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by sub-segment (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors)) and Devices ( Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood Glucose and Continuous Glucose Monitoring)).

By Drug
Oral anti-diabetic drugs
Biguanide (Value and Volume 2012-2025)
Metformin
Alpha - Glucosidase inhibitors (Value and Volume 2012-2025)
Alpha - Glucosidase inhibitors
Dopamine -D2 receptor agonist (Value and Volume 2012-2025)
Bromocriptin( Cycloset)
Sodium - glucose cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2025)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl peptidase - 4 (DPP-4) inhibitors (Value and Volume 2012-2025)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas (Value and Volume 2012-2025)
Sulfonylureas
Meglitinide (Value and Volume 2012-2025)
Meglitinide
Insulin (Value and Volume 2012-2025)
Basal or Long Acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
FIASP (Insulin Aspart)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Combination Insulins (Value and Volume 2012-2025)
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Soliqua/Suliqua (Insulin Glargine and Lixisenatide)
Oral Combination (Value and Volume 2012-2025)
Janumet (Sitagliptin and Metformin HCl)
Non-Insulin Injectable drugs (Value and Volume 2012-2025)
GLP1 receptor agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue (Value and Volume 2012-2025)
Symlin (Pramlintide)
By Devices
By Monitoring Devices (Value, and Volume, 2012-2025)
Self-Monitoring Blood Glucose
Glucometer Devices
Blood Glucose Test Strips
Lancets
Continuous Glucose Monitoring (Value, and Volume, 2012-2025)
Sensors
Durables
By Management Devices (Value, and Volume, 2012-2025)
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Insulin Syringes
Cartridges in Reusable pens
Insulin Disposable Pens
Jet Injectors

Report scope can be customized per your requirements. Click here.

Key Market Trends

Sulfonylureas and Metformin held 67% of share in the Canada oral diabetes drugs market in 2019

In 2019, Metformin holds 28.64% of the market share in Canada diabetes drugs and devices market. Metformin has proved to be an effective medication for diabetes treatment when the diet is not enough to provide a healthy way of life. Rather than other drugs that stimulate the release of insulin, metformin increases the body's sensitivity to insulin, thus, helping in reducing a patient’s blood sugar level. Asia-Pacific holds the highest market share due to many generic players in the Metformin market. Sulfonylureas hold the highest market in Canada oral diabetes drugs market, second-generation Sulfonylureas which have fewer side effects, include Glipizide (Glucotrol), Glyburide (Micronase, Glynase PresTabs, and DiaBeta), and the newest drug, Glimepiride (Amaryl). A single-dose, extended-release form of Glipizide called Glucotrol XL is also available.

Canada-Devices-Market1

Monitoring Devices recorded the Highest Market Share in the Canada Diabetes Devices Market

In Canada Diabetes Devices monitoring Devices, Monitoring Devices holds 48.7% of the market share in 2019. The personal-use glucometer is expected to see high sales in the future, owing to the rising awareness and reducing costs associated with the glucometer. Due to favorable healthcare insurance policies, the glucometer segment of the market studied is expected to witness high growth, during the forecast period. Canada Monitoring Devices market increasing is due to the increase in Continuous Glucose Monitoring Devices (CGM) usage. In 2019, DexCom Inc., launched the Dexcom G6 CGM System for people with diabetes ages two years and up in Canada.

canada-Devices-Geography-Market2

Competitive Landscape

There have been constant innovations driven by manufacturers to compete in the market. The major players, such as Abbott and Medtronic, have undergone many mergers, acquisitions, and partnerships, to establish market dominance, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies. The manufacturers of insulin delivery devices are spending a massive amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may help to enable insulin data to be shared between Novo Nordisk connected insulin pens and digital health tools compatible with the FreeStyle Libre portfolio of products. Mega Blockbuster Lantus, manufactured by Sanofi, led the basal insulin field. Lantus generated global sales of more than USD 7 billion at its peak in 2014. In 2019, DexCom Inc. is now accepting orders for the Dexcom G6 CGM System for people with diabetes ages two years and up in Canada.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Drivers

    2. 4.2 Market Restraints

  5. 5. Market Segmentation

    1. 5.1 By Drug

      1. 5.1.1 Oral anti-diabetic drugs

        1. 5.1.1.1 Biguanide (Value and Volume 2012-2025)

          1. 5.1.1.1.1 Metformin

        2. 5.1.1.2 Alpha - Glucosidase inhibitors (Value and Volume 2012-2025)

          1. 5.1.1.2.1 Alpha - Glucosidase inhibitors

        3. 5.1.1.3 Dopamine -D2 receptor agonist (Value and Volume 2012-2025)

          1. 5.1.1.3.1 Bromocriptin( Cycloset)

        4. 5.1.1.4 Sodium - glucose cotransport -2 (SGLT-2) inhibitor (Value and Volume 2012-2025)

          1. 5.1.1.4.1 Invokana (Canagliflozin)

          2. 5.1.1.4.2 Jardiance (Empagliflozin)

          3. 5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)

          4. 5.1.1.4.4 Suglat (Ipragliflozin)

        5. 5.1.1.5 Dipeptidyl peptidase - 4 (DPP-4) inhibitors (Value and Volume 2012-2025)

          1. 5.1.1.5.1 Januvia (Sitagliptin)

          2. 5.1.1.5.2 Onglyza (Saxagliptin)

          3. 5.1.1.5.3 Tradjenta (Linagliptin)

          4. 5.1.1.5.4 Vipidia/Nesina (Alogliptin)

          5. 5.1.1.5.5 Galvus (Vildagliptin)

        6. 5.1.1.6 Sulfonylureas (Value and Volume 2012-2025)

          1. 5.1.1.6.1 Sulfonylureas

        7. 5.1.1.7 Meglitinide (Value and Volume 2012-2025)

          1. 5.1.1.7.1 Meglitinide

      2. 5.1.2 Insulin (Value and Volume 2012-2025)

        1. 5.1.2.1 Basal or Long Acting Insulins

          1. 5.1.2.1.1 Lantus (Insulin Glargine)

          2. 5.1.2.1.2 Levemir (Insulin Detemir)

          3. 5.1.2.1.3 Toujeo (Insulin Glargine)

          4. 5.1.2.1.4 Tresiba (Insulin Degludec)

          5. 5.1.2.1.5 Basaglar (Insulin Glargine)

        2. 5.1.2.2 Bolus or Fast Acting Insulins

          1. 5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

          2. 5.1.2.2.2 Humalog (Insulin Lispro)

          3. 5.1.2.2.3 Apidra (Insulin Glulisine)

          4. 5.1.2.2.4 FIASP (Insulin Aspart)

        3. 5.1.2.3 Traditional Human Insulins

          1. 5.1.2.3.1 Novolin/Actrapid/Insulatard

          2. 5.1.2.3.2 Humilin

      3. 5.1.3 Combination Insulins (Value and Volume 2012-2025)

        1. 5.1.3.1 NovoMix (Biphasic Insulin Aspart)

        2. 5.1.3.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

        3. 5.1.3.3 Xultophy (Insulin Degludec and Liraglutide)

        4. 5.1.3.4 Soliqua/Suliqua (Insulin Glargine and Lixisenatide)

      4. 5.1.4 Oral Combination (Value and Volume 2012-2025)

        1. 5.1.4.1 Janumet (Sitagliptin and Metformin HCl)

      5. 5.1.5 Non-Insulin Injectable drugs (Value and Volume 2012-2025)

        1. 5.1.5.1 GLP1 receptor agonists

          1. 5.1.5.1.1 Victoza (Liraglutide)

          2. 5.1.5.1.2 Byetta (Exenatide)

          3. 5.1.5.1.3 Bydureon (Exenatide)

          4. 5.1.5.1.4 Trulicity (Dulaglutide)

          5. 5.1.5.1.5 Lyxumia (Lixisenatide)

        2. 5.1.5.2 Amylin Analogue (Value and Volume 2012-2025)

          1. 5.1.5.2.1 Symlin (Pramlintide)

    2. 5.2 By Devices

      1. 5.2.1 By Monitoring Devices (Value, and Volume, 2012-2025)

        1. 5.2.1.1 Self-Monitoring Blood Glucose

          1. 5.2.1.1.1 Glucometer Devices

          2. 5.2.1.1.2 Blood Glucose Test Strips

          3. 5.2.1.1.3 Lancets

        2. 5.2.1.2 Continuous Glucose Monitoring (Value, and Volume, 2012-2025)

          1. 5.2.1.2.1 Sensors

          2. 5.2.1.2.2 Durables

      2. 5.2.2 By Management Devices (Value, and Volume, 2012-2025)

        1. 5.2.2.1 Insulin Pump

          1. 5.2.2.1.1 Insulin Pump Device

          2. 5.2.2.1.2 Insulin Pump Reservoir

          3. 5.2.2.1.3 Infusion Set

        2. 5.2.2.2 Insulin Syringes

        3. 5.2.2.3 Cartridges in Reusable pens

        4. 5.2.2.4 Insulin Disposable Pens

        5. 5.2.2.5 Jet Injectors

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetic Population (2012-2025)

    2. 6.2 Type-2 Diabetic Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Novo Nordisk A/S

      2. 7.1.2 Sanofi Aventis

      3. 7.1.3 Eli Lilly

      4. 7.1.4 AstraZeneca

      5. 7.1.5 AstraZeneca

      6. 7.1.6 Boehringer Ingelheim

      7. 7.1.7 Bristol Myers Squibb

      8. 7.1.8 Roche

      9. 7.1.9 Abbott

      10. 7.1.10 Johnson and Johnson (Lifescan)

      11. 7.1.11 Arkray

      12. 7.1.12 Ascensia Diabetes Care

      13. 7.1.13 AgaMatrix Inc.

      14. 7.1.14 Dexcom

      15. 7.1.15 Medtronic

      16. 7.1.16 Becton Dickinson

      17. 7.1.17 Ypsomed Holding AG

      18. 7.1.18 Ypsomed Holding AG

      19. 7.1.19 Terumo

      20. 7.1.20 LMC Diabetes and Endocrinology

      21. 7.1.21 Bayshore Health Care

      22. 7.1.22 Express Scripts

      23. 7.1.23 One Drop

      24. 7.1.24 Telus Health

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Canada Diabetes Care Drugs and Devices Market market is studied from 2018 - 2026.

The Canada Diabetes Care Drugs and Devices Market is growing at a CAGR of >5% over the next 5 years.

Roche, Medtrionic, Sanofi, Novo Nordisk, Omnipod are the major companies operating in Canada Diabetes Care Drugs and Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!